Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
Vivos Therapeutics, Inc. (VVOS)
Company Research
Source: GlobeNewswire
LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered for resale pursuant to an effective registration statement on Form S-3 (Registration No. 333- 278564). The gross proceeds to the company from the exercise of the warrants were approximately $4.64 million, prior to deducting placement agent fees and offering expenses. H.C. Wainwright & Co. acted as the exclusive placeme
Show less
Read more
Impact Snapshot
Event Time:
VVOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VVOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VVOS alerts
High impacting Vivos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VVOS
News
- Vivos Therapeutics (NASDAQ:VVOS) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross ProceedsGlobeNewswire
- Vivos Therapeutics, Inc. (VVOS) Discusses Strategic Business Model Pivot and Transition in Sleep Apnea Treatment Approach Transcript [Seeking Alpha]Seeking Alpha
- Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, MichiganGlobeNewswire
- Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST [Yahoo! Finance]Yahoo! Finance
VVOS
Earnings
- 11/19/25 - Beat
VVOS
Sec Filings
- 1/20/26 - Form 8-K
- 1/16/26 - Form 8-K
- 1/14/26 - Form 424B3
- VVOS's page on the SEC website